Welcome to our dedicated page for Lucid Diagnostics news (Ticker: LUCD), a resource for investors and traders seeking the latest updates and insights on Lucid Diagnostics stock.
Lucid Diagnostics Inc. reports developments in commercial-stage cancer prevention diagnostics for patients with gastroesophageal reflux disease who are at risk for esophageal precancer and esophageal adenocarcinoma. The company, a subsidiary of PAVmed Inc., markets the EsoGuard Esophageal DNA Test and uses the EsoCheck Esophageal Cell Collection Device to collect samples through a brief, noninvasive office procedure.
Recurring updates cover EsoGuard commercialization, healthcare-system access, clinical evidence for esophageal precancer detection, quarterly business results, cash resources, and conference presentations. Lucid news also includes capital actions such as registered common stock offerings and related use of proceeds for working capital and general corporate purposes.
PAVmed (NASDAQ: PAVM) will implement a 1-for-30 reverse stock split of its common stock effective January 2, 2026 at 12:01 a.m. ET, with shares trading on a split-adjusted basis at the market open that day. The reverse split is intended to bring the company into compliance with Nasdaq's $1.00 minimum bid requirement.
The board approved the 1-for-30 ratio on December 8, 2025 following shareholder approval at a December 5, 2025 special meeting. As effective, authorized common shares will be reduced from 250,000,000 to 25,000,000. Equity awards, outstanding options, convertible securities, and employee purchase plan shares will be proportionately adjusted. No fractional shares will be issued; fractional holdings will be rounded up to the nearest whole share. New CUSIP: 70387R502.
Lucid Diagnostics (Nasdaq: LUCD) reported real-world data from an 18-month retrospective analysis of 11,991 at-risk patients who underwent EsoCheck cell collection and EsoGuard DNA testing between January 2023 and June 2024.
Key findings: 95% technical success, 95% of collections completed in under two minutes, and no serious adverse events. Authors concluded the results show safety, tolerability, scalability, and appropriate physician use consistent with prior studies.
Lucid Diagnostics (Nasdaq: LUCD) was named the winner in its company size category in the GenomeWeb 2025 Best Places to Work program on November 20, 2025.
The award recognizes top workplaces across diagnostics and precision medicine for transparent communication, an inclusive environment, professional development, and collaborative culture. Lucid is described as a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed (Nasdaq: PAVM). Company leadership credited employees for the recognition and emphasized a focus on patients, culture, scientific rigor, and long-term commercial success.
Lucid Diagnostics (Nasdaq: LUCD) will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025 in New York City.
Dennis McGrath, Lucid's Chief Financial Officer, will be available for one-on-one investor meetings; meetings must be scheduled through a Canaccord Genuity representative.
PAVmed (NASDAQ: PAVM) and subsidiaries Lucid Diagnostics (NASDAQ: LUCD) and Veris Health provided a business update and reported 3Q25 results on November 13, 2025. Key operating items: Lucid recognized $1.2M of EsoGuard revenue and processed 2,841 tests, and a Medicare Contractor Advisory Committee meeting showed unanimous expert support for Medicare coverage. Lucid completed an underwritten offering netting approximately $27.0M. Veris launched commercial deployment with OSU James and relaunched development of an implantable physiological monitor ahead of a planned 2026 510(k) submission. Financials: consolidated revenue was $5K for the quarter, GAAP net loss attributable to common stockholders was approximately $6.3M (loss per diluted share $(0.29)), non-GAAP adjusted loss was approximately $0.4M, and cash and cash equivalents totaled $3.1M.
Lucid Diagnostics (Nasdaq: LUCD) reported 3Q25 EsoGuard revenue of $1.2M from 2,841 tests processed, GAAP net loss of $10.4M (GAAP EPS $(0.10)), and non-GAAP adjusted loss of $10.3M ($(0.10) per share).
The company completed a public offering netting $27.0M, ended 3Q25 with $47.3M cash proforma, and said this extends runway through 2026 and past upcoming reimbursement milestones. A MolDx CAC meeting produced a unanimous expert consensus supporting Medicare coverage for EsoGuard, a key step in LCD reconsideration.
PAVmed (NASDAQ: LUCD) will host a business update conference call and webcast on November 13, 2025 at 8:30 AM ET. The call will feature Lishan Aklog, M.D., chairman and CEO, providing an overview of operations and growth strategy, and Dennis McGrath, president and CFO, discussing the company’s third quarter 2025 financial results.
The live webcast will be available in the investor relations section of pavmed.com. U.S. callers can join by dialing 1-800-836-8184; international listeners can dial 1-646-357-8785 and should request the conference name "PAVmed Business Update." A replay will be available on the investor relations website for 30 days after the call.
Lucid Diagnostics (Nasdaq: LUCD) will hold a business update conference call and webcast on Wednesday, November 12, 2025 at 8:30 AM ET. Management will include Lishan Aklog, M.D., chairman and CEO, who will provide a business update and growth strategy overview, and Dennis McGrath, CFO, who will discuss third quarter 2025 financial results. The webcast will be available in the investor relations section at luciddx.com. U.S. dial-in is 1-800-836-8184; international dial-in is 1-646-357-8785; ask the operator for the conference call name "Lucid Diagnostics Business Update" to join. A replay will be available for 30 days on the investor relations site.
Lucid Diagnostics (Nasdaq: LUCD) will participate in the 2025 Maxim Growth Summit in New York City on October 22-23, 2025.
Dennis McGrath, Lucid's Chief Financial Officer, will hold one-on-one investor meetings during the conference; investors should contact their Maxim representative to schedule meetings. Registration and event details are available through the Maxim Growth Summit event page.
Lucid Diagnostics (Nasdaq: LUCD) has appointed Danielle Scelfo as Senior Vice President of Market Access & Government Affairs. Scelfo, a veteran with over 25 years of experience in healthcare policy and market access, will focus on expanding insurance coverage and patient access for the company's EsoGuard® Esophageal DNA Test.
The appointment comes at a crucial time following a positive MolDX CAC meeting that suggests Medicare coverage is approaching. Scelfo's previous experience includes leadership roles at ClearNote Health, CareDx, Hologic, and other prominent healthcare companies. She will leverage her expertise to strengthen Lucid's market access infrastructure and accelerate commercial coverage expansion.